Table 3.
Asthma control and QoL at baseline and after benralizumab treatment initiation
| Variables | Baseline | After treatment initiation |
|---|---|---|
| Lung function | ||
| Pre-BD FEV1 (mL), N = 10 | ||
| Mean (SD) | 1,827 (505.9) | 1,982 (459.9) |
| Difference, mean (SD) | 155 (430.4) | |
| p-value* | 0.284 | |
| Pre-BD FEV1 (%), N = 10 | ||
| Mean (SD) | 63 (18.8) | 68.9 (20.7) |
| Difference, mean (SD) | 5.8 (17.3) | |
| p-value* | 0.314 | |
| Pre-BD FEV1/FVC (%), N = 10 | ||
| Mean (SD) | 59.8 (9.9) | 56.2 (24.2) |
| Difference, mean (SD) | − 3.6 (20) | |
| p-value* | 0.441 | |
| Post-BD FEV1 (mL), N = 9 | ||
| Mean (SD) | 2,093.3 (995.8) | 2,350 (1,062.9) |
| Difference, mean (SD) | 256.7 (400.6) | |
| p-value* | 0.091 | |
| Post-BD FEV1 (%), N = 9 | ||
| Mean (SD) | 66.2 (22.1) | 73.5 (24.3) |
| Difference, mean (SD) | 7.3 (13.6) | |
| p-value* | 0.147 | |
| Post-BD FEV1/FVC (%), N = 9 | ||
| Mean (SD) | 65.2 (11.8) | 67.4 (12.5) |
| Difference, mean (SD) | 2.2 (5.8) | |
| p-value* | 0.291 | |
| Blood eosinophil count (cells/μL), N = 13 | ||
| Mean (SD) | 490 (353.9) | 0.8 (2.8) |
| Difference, mean (SD) | − 489.2 (354.4) | |
| p-value* | 0.002 | |
| OCS | N = 27 | N = 19 |
| OCS-dependent, n (%) | 24 (88.9) | 15 (78.9) |
| OCS dose reduction ≥ 50%, n (%) | 6 (31.6)a | |
| Oral prednisone (mg/day), N = 15 | ||
| Mean (SD) | 15.1 (15.8) | 21.8 (18.6) |
| Difference, mean (SD) | 6.7 (2.8) | |
| p-value* | 0.144 | |
| ACT, N = 15 | ||
| Mean (SD) | 14.8 (6.8) | 18.1 (6.3) |
| Difference, mean (SD) | 3.3 (6.8) | |
| p-value* | 0.079 | |
| Clinically meaningful difference (≥ 3), n (%) | 9 (60) | |
| miniAQLQ, N = 5 | ||
| Mean (SD) | 3.6 (0.8) | 4.7 (1.5) |
| Difference, mean (SD) | 1.2 (1.9) | |
| p-value* | 0.236 | |
| Clinically meaningful difference (≥ 0.5), n(%) | 2 (40) | |
ACT Asthma Control Test, AQLQ Asthma Quality of Life Questionnaire, BD bronchodilator, FEV1 forced expiratory volume in 1 s, FVC forced vitality capacity, μL microliter, mL millilitre, OCS oral corticosteroids, SD standard deviation
*Paired T-test
aData unknown in 6 cases after benralizumab treatment (31.6%)